IL-38 Ameliorates Skin Inflammation and Limits IL-17 Production from γδ T Cells
Author(s) -
Yingying Han,
Javier Mora,
Arnaud Huard,
Priscila da Silva,
Svenja Wiechmann,
Mateusz Putyrski,
Christian Schuster,
Eiman Elwakeel,
Guang-Ping Lang,
Anica Scholz,
Tatjana Scholz,
Tobias Schmid,
Natasja de Bruin,
Pierre Billuart,
Carlo Sala,
Harald Burkhardt,
Michael J. Parnham,
Andreas Ernst,
Bernhard Brüne,
Andreas Weigert
Publication year - 2019
Publication title -
cell reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.264
H-Index - 154
eISSN - 2639-1856
pISSN - 2211-1247
DOI - 10.1016/j.celrep.2019.03.082
Subject(s) - inflammation , production (economics) , immunology , chemistry , medicine , microbiology and biotechnology , biology , macroeconomics , economics
Interleukin-38 (IL-38) is a cytokine of the IL-1 family with a role in chronic inflammation. However, its main cellular targets and receptors remain obscure. IL-38 is highly expressed in the skin and downregulated in psoriasis patients. We report an investigation in cellular targets of IL-38 during the progression of imiquimod-induced psoriasis. In this model, IL-38 knockout (IL-38 KO) mice show delayed disease resolution with exacerbated IL-17-mediated inflammation, which is reversed by the administration of mature IL-38 or γδ T cell-receptor-blocking antibodies. Mechanistically, X-linked IL-1 receptor accessory protein-like 1 (IL1RAPL1) is upregulated upon γδ T cell activation to feedforward-amplify IL-17 production and is required for IL-38 to suppress γδ T cell IL-17 production. Accordingly, psoriatic IL1RAPL1 KO mice show reduced inflammation and IL-17 production by γδ T cells. Our findings indicate a role for IL-38 in the regulation of γδ T cell activation through IL1RAPL1, with consequences for auto-inflammatory disease.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom